Evidence map›Paper›PMID 30007095›Full record

ReviewCancer science2018

Heterogeneity of tumor lymphangiogenesis: Progress and prospects.

Xueting Hu, Jincai Luo

Abstract readReview
In one paragraph

Review in Cancer science, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Article
  2. Review
  3. Lymphatic transport in anti-tumor immunity and metastasis.The Journal of experimental medicine · 2025
    Review
  4. Article
  5. Advances in lymphatic metastasis of non-small cell lung cancer.Cell communication and signaling : CCS · 2024
    Review
  6. Article
  7. Review
  8. Article
  9. Lymphangiogenesis in gastric cancer: function and mechanism.European journal of medical research · 2023
    Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Xueting HuBeijing Key Laboratory of Cardiometabolic Molecular Medicine, Institute of Molecular Medicine, Peking University, Beijing, China.
Jincai LuoBeijing Key Laboratory of Cardiometabolic Molecular Medicine, Institute of Molecular Medicine, Peking University, Beijing, China.ORCID http://orcid.org/0000-0002-9614-8776

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lymphangiogenesis and increased expression of lymphangiogenic growth factors are associated with high rates of lymph node (LN) metastasis and with poor prognosis in some, but not all, solid tumors. In addition to its involvement in metastasis, lymphangiogenesis has been shown to have other roles in tumor pathogenesis, such as the niche function of tumor stem cells and regulatory functions of antitumor immune responses. In contrast, evidence has accumulated that tumor-induced lymphangiogenesis displays the heterogeneity in gene signature, structure, cellular origins and functional plasticity. This review summarizes the advances in the research on the heterogeneity of tumor lymphangiogenesis and discusses how it may contribute to functional complexity and multiplicity of lymphangiogenesis in tumor progression.

Indexed as

Gene Expression Regulation, NeoplasticBiomarkers, TumorDisease ProgressionEndothelial CellsHumansLymphangiogenesisLymphatic MetastasisLymphatic VesselsLymph NodesNeoplasmsBiomarkers, Tumorheterogeneityimmunitylymphatic endothelial cellmetastasistumor lymphangiogenesis

Identifiers

PMID30007095
PMCPMC6172057

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.